 |
 |
Reducing Stroke Risk in Older Adults with Atrial Fibrillation
Release Date: August-25-10
UAN: 203-999-10-069-C01-P
|
|
|
|
 |
 |
|
Jointly Sponsored by the American Society of Consultant Pharmacists and Medical Communications Media, Inc. |
|
|
|
 |
|
|
| This knowledge-based educational activity is designed to meet the needs of healthcare professionals in eldercare settings, including consultant and VA pharmacists, medical directors, gerontological nurse practitioners, long-term care nurses, and other pharmacists, physicians, physician assistants, nurse practitioners, and nurses involved in the care of older patients with atrial fibrillation. |
|
|
|
 |
|
|
|
|
|
 |
|
|
|
|
|
 |
|
|
Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common cardiac arrhythmia, and the risk for stroke in these patients is substantial. In older adults, AF leads to 25% of all strokes. Guidelines for the management of patients with AF emphasize risk assessment to determine which patients are likely to benefit from anticoagulant therapy. Long-term anticoagulation is recommended for all AF patients who have risk factors for thromboembolism. Many older adults with AF receive inadequate risk assessment, however, and anticoagulation therapy is often not initiated or optimized.
Senior care clinicians play an important role in ensuring that older adults with AF benefit from optimal anticoagulant therapy to prevent stroke. This activity seeks to enhance clinicians' abilities to determine when the risk for stroke in elderly patients with AF exceeds the risk for anticoagulation-associated bleeding, to identify optimal anticoagulant agents, and to maintain the ideal therapeutic range for therapy for each patient. Emerging anticoagulants and their unique characteristics will also be discussed. Because of the serious and immediate consequences of strokes, effective preventive treatment is of the utmost importance in reducing disability and improving survival in elderly patients with AF.
|
|
|
|
 |
|
|
|
|
|
 |
|
|
Robert Lee Page II, PharmD, MSPH, FCCP, FAHA, BCPS
Associate Professor
Department of Clinical Pharmacy
Associate Professor
Department of Physical Medicine/Rehabilitation
University of Colorado School of Pharmacy
Aurora, CO
Steven Rothman, MD, FACC
Clinical Associate Professor
Lankenau Institute of Medical Research
Campus Chief, Cardiovascular Diseases
Lankenau Hospital, MLH Heart Center
Wynnewood, PA
|
|
|
|
 |
|
|
It is the policy of ASCP, AKH Inc, and NADONA/LTC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activities or with the commercial supporter of these continuing education activities. Identified conflict of interest is resolved by the providers prior to accreditation of the activities. ASCP, AKH Inc, and NADONA/LTC planners and reviewers have no relevant financial relationships to disclose.
Dr. Page discloses that he has served on the speakers' bureau for AstraZeneca and Dr. Rothman discloses that he has served as a consultant for AstraZeneca and on the speakers' bureau for sanofi-aventis. |
|
|
|
 |
|
|
Pharmacy Continuing Education: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity (UAN: 203-999-10-069-C01-P) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU). |
|
Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number 030803. AKH Inc. designates this educational activity for 1 contact hour.
|
|
Nursing Continuing Education: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 1 contact hour by NADONA/LTC.
Participants must successfully complete the post test (70% or higher) and submit an evaluation to receive credit. A statement of credit will be available immediately if the post-test and evaluation are completed online, or mailed within 4-6 weeks if they are submitted by mail. There is no fee to participate in this activity.
|
|
|
|
|
|
 |
|
|
Supported through an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. |
|
|
|
|
|
 |
|
|
|
|
| |
|
|
|
|
Wednesday, September 08, 2010
12:00 PM |
|
|
|
Monday, September 13, 2010
03:00 PM |
|
|
|
Tuesday, September 14, 2010
12:00 PM |
|
|
|
Wednesday, September 22, 2010
01:00 PM |
|
|
|
Thursday, September 23, 2010
07:00 PM |
|
|
|
Thursday, September 30, 2010
12:00 PM |
|
|
|
Monday, October 04, 2010
03:00 PM |
|
|
|
|
|
